NFE2L2 and non-small cell lung carcinoma: A pooled analysis of two independent cohorts of 853 advanced NSCLC patients showed that 171 (20.0%) harbored KEAP1/NFE2L2 mutations, comprising 211 patients from the POPLAR trial (49 [23.2%] with KEAP1/NFE2L2 mutations) and 642 from the OAK trial (122 [19.0%] with KEAP1/NFE2L2 mutations).